SCHEMBL24974592

SCHEMBL24974592

COc1ccc(OC)c(N2CC(C(=O)Nc3ccc(-c4cn(CCCC(=O)O)nn4)cc3)CC2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.46
▸ POLB P06746 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ HDAC3 O15379 4/20 0.44
▸ HDAC4 P56524 4/20 0.44
▸ HDAC1 Q13547 4/20 0.44
▸ HDAC7 Q8WUI4 4/20 0.44
▸ HDAC2 Q92769 4/20 0.44
▸ HDAC10 Q969S8 4/20 0.44
▸ HDAC11 Q96DB2 4/20 0.44
▸ HDAC8 Q9BY41 4/20 0.44
▸ HDAC6 Q9UBN7 4/20 0.44
▸ HDAC9 Q9UKV0 4/20 0.44
▸ HDAC5 Q9UQL6 4/20 0.44
▸ DRD2 P14416 1/20 0.43
▸ DRD4 P21917 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21152067 0.91 POLB (0.47) ALDH1A1POLBTSHRMAPTKDR
SCHEMBL24974573 0.87 HDAC1 (0.42) ALDH1A1POLBTSHRHDAC3HDAC4
SCHEMBL24974737 0.87 HDAC1 (0.42) ALDH1A1POLBTSHRHDAC3HDAC4
SCHEMBL24974634 0.83 POLB (0.56) ALDH1A1POLBDRD2DRD4DRD3
SCHEMBL24974541 0.82 ALDH1A1 (0.52) ALDH1A1POLBTSHRKDRUSP2
SCHEMBL24974742 0.80 MAPT (0.58) ALDH1A1POLBMAPT
SCHEMBL24974782 0.79 MAPT (0.58) ALDH1A1POLBTSHRMAPTUSP2
SCHEMBL24974776 0.76 PKM (0.49) KDR
SCHEMBL24974601 0.75 ROCK2 (0.54) ALDH1A1POLBTSHRMAPT
SCHEMBL24974637 0.75 KMT2A (0.48) ALDH1A1POLBMAPTKDRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B ALDH1A1 1203/4885POLB 4058/4885TSHR 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback